ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

2025-522288-13-00 · tracked via the Priya Life Science EU tracker

Sponsor

ETOP IBCSG Partners Foundation

Sponsor type

Laboratory/Research/Testing facility

Therapeutic area

Neoplasms

Decision date

08/04/2026

Enrollment target

Sites

France, Greece, Spain, Italy

Condition studied

Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

Investigational medicinal product(s)

TarlatamabTarlatamab

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Overall survival rate at 12 months (12-month OS)

Endpoint detail

Objective response rate (ORR) according to RECIST v1.1, Duration of response (DoR), Disease control rate (DCR), Progression-free survival (PFS) according to RECIST v1.1, Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria and TLS that are graded according to the Cairo-Bishop classification

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522288-13-00 on CTIS ↗ ← All trials in the EU